Table 3.
Univariate analysis of factors influencing survival (n=33)
| Subgroup | HR | 95% CI | P-value |
|---|---|---|---|
| Progression-free survival | |||
| ECOG performance status | |||
| 0 | 0.37 | 0.12–1.15 | |
| 1 | 1 | 0.085 | |
| Site of primary tumor | |||
| Colon | 0.48 | 0.20–1.19 | |
| Rectum | 1 | 0.113 | |
| Adjuvant treatment | |||
| No | 1 | ||
| Yes | 0.35 | 0.14–0.88 | 0.026 |
| Number of metastatic sites | |||
| 1 | 0.30 | 0.09–1.03 | |
| ≥2 | 1 | 0.055 | |
| DC after 12 weeks of treatment starting | |||
| No | 1 | ||
| Yes | 0.20 | 0.08–0.51 | 0.001 |
| Overall survival | |||
| Sex | |||
| Male | 0.36 | 0.16–0.80 | |
| Female | 1 | 0.012 | |
| Histology | |||
| Well or moderately | 0.07 | 0.01–0.81 | |
| Poor | 1 | 0.033 | |
| Number of metastatic sites | |||
| 1 | 0.35 | 0.12–1.05 | |
| ≥2 | 1 | 0.062 | |
| DC after 12 weeks of treatment starting | |||
| No | 1 | ||
| Yes | 0.49 | 0.22–1.12 | 0.090 |
Abbreviations: CI, confidence interval; DC, disease control; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio.